Arbor Biotechnologies to Participate in Upcoming Healthcare Investor Conferences

CAMBRIDGE, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) — Arbor Biotechnologies, a biotechnology company discovering and developing the next generation of genetic medicines, today announced its participation in upcoming healthcare investor conferences in September and October.

Conference Details:

Event: Jefferies Cell & Genetic Medicine Summit
Date/Time: Thursday, September 29th at 8:30 a.m. ET
Location: New York, NY
Format: Corporate Presentation
Event: Chardan 6th Annual Genetic Medicines Conference
Date/Time: Monday, October 3rd at 9:30 a.m. ET and 11:30 a.m. ET
Location: New York, NY
Format: Panel and Corporate Presentation, respectively
Event: BMO Biopharma Spotlight Series: Gene Editing & Therapeutics
Date/Time: Thursday, October 6th at 12:00 p.m. ET
Location: Virtual
Format: Panel
Event: Oppenheimer Private Company Showcase
Date/Time: Tuesday, October 18th at 2:10 p.m. PT
Location: Palo Alto, CA
Format: Corporate Presentation

A webcast of the Jefferies Cell & Genetic Medicine Summit presentation will be accessible through the News Section of the company’s website at, with a replay available for 90 days following the event.

About Arbor Biotechnologies
Arbor Biotechnologies is a next-generation gene editing company focused on discovering and developing potentially curative genomic medicines. Founded by Feng Zhang, David Walt, David Scott, and Winston Yan, our proprietary discovery engine is focused on discovering genetic editing capabilities spanning knockdowns to whole gene insertions, which has enabled us to generate the most extensive toolbox of proprietary genomic editors in the industry to date. Leveraging our wholly-owned nucleases as the chassis for genetic modification, we can work backward from disease pathology to choose the optimal editing approach that specifically addresses the underlying cause of disease, resulting in a potentially curative medicine for a wider range of genetic disorders. As Arbor continues to advance its pipeline toward the clinic with an initial focus in liver and CNS disease, the Company has also secured several partnerships around gene editing and ex vivo cell therapy programs to broaden the reach of its novel nuclease technology. For more information, visit


Amy Bonanno, Solebury Strategic Communications
[email protected]

Investor Relations
Alexandra Roy, Solebury Strategic Communications
[email protected]

error: Content is protected !!